Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases | Zendy

Beiying Qiu | Zendy; Allison Tan | Zendy; Veluchamy A. Barathi | Zendy; Yong Li | Zendy; Hannah Murray | Zendy; Wei Cheng | Zendy; Chenghao Liu | Zendy; Joanna Marie Fianza Busoy | Zendy; Qi-Yin Chen | Zendy; Srivani Sistla | Zendy; Walter Hunziker | Zendy; Chui Ming Gemmy Cheung | Zendy; Tien Yin Wong | Zendy; Wanjin Hong | Zendy; Hendrik Luesch | Zendy; Xiaomeng Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases

Author(s) -

Beiying Qiu,

Allison Tan,

Veluchamy A. Barathi,

Yong Li,

Hannah Murray,

Wei Cheng,

Chenghao Liu,

Joanna Marie Fianza Busoy,

Qi-Yin Chen,

Srivani Sistla,

Walter Hunziker,

Chui Ming Gemmy Cheung,

Tien Yin Wong,

Wanjin Hong,

Hendrik Luesch,

Xiaomeng Wang

Publication year - 2019

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.19-26936

Subject(s) - angiogenesis , neovascularization , medicine , in vivo , vascular endothelial growth factor , choroidal neovascularization , ex vivo , retinal , cancer research , pharmacology , immunology , pathology , biology , ophthalmology , microbiology and biotechnology , vegf receptors

Abnormal blood vessel formation is a defining feature of many blinding eye diseases. Targeting abnormal angiogenesis by inhibiting VEGF has revolutionized the treatment of many ocular angiogenic diseases over the last decade. However, a substantial number of patients are refractory to anti-VEGF treatment or may develop resistance over time. The objective of this study was to determine the efficacy and the mechanism of action of Apratoxin S4 in ocular angiogenesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research